These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 38945393)

  • 21. Recent survey on nanosuspension: a patent overview.
    Jethara SI; Patel AD; Patel MR; Patel MS; Patel KR
    Recent Pat Drug Deliv Formul; 2015; 9(1):65-78. PubMed ID: 25354346
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nanosuspensions - An Update on Recent Patents, Methods of Preparation, and Evaluation Parameters.
    Khanuja HK; Awasthi R; Mehta M; Satija S; Aljabali AAA; Tambuwala MM; Chellappan DK; Dua K; Dureja H
    Recent Pat Nanotechnol; 2021; 15(4):351-366. PubMed ID: 33357187
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preparation of Piroxicam nanosuspensions by high pressure homogenization and evaluation of improved bioavailability.
    Aksoy OA; Zanbak Çotaoğlu M; Fatsa T; Topal GR; Eşim Ö; Göksel BA; Hoşbul T; Özkan CK; Savaşer A; Özkan Y
    Drug Dev Ind Pharm; 2023 Dec; 49(12):715-722. PubMed ID: 38087641
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dermal flurbiprofen nanosuspensions: Optimization with design of experiment approach and in vitro evaluation.
    Oktay AN; Karakucuk A; Ilbasmis-Tamer S; Celebi N
    Eur J Pharm Sci; 2018 Sep; 122():254-263. PubMed ID: 29981401
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug nanosuspensions: a ZIP tool between traditional and innovative pharmaceutical formulations.
    Leone F; Cavalli R
    Expert Opin Drug Deliv; 2015; 12(10):1607-25. PubMed ID: 25960000
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A brief literature and patent review of nanosuspensions to a final drug product.
    Chin WW; Parmentier J; Widzinski M; Tan EH; Gokhale R
    J Pharm Sci; 2014 Oct; 103(10):2980-99. PubMed ID: 25099918
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Exploring the influence factors and improvement strategies of drug polymorphic transformation combined kinetic and thermodynamic perspectives during the formation of nanosuspensions.
    Meng T; Qiao F; Ma S; Gao T; Li L; Hou Y; Yang J
    Drug Dev Ind Pharm; 2021 Dec; 47(12):1867-1880. PubMed ID: 35362347
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nanosuspensions of poorly water soluble drugs prepared by top-down technologies.
    Zhang X; Li LC; Mao S
    Curr Pharm Des; 2014; 20(3):388-407. PubMed ID: 23651400
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nasal delivery of nanosuspension-based mucoadhesive formulation with improved bioavailability of loratadine: Preparation, characterization, and in vivo evaluation.
    Alshweiat A; Csóka I; Tömösi F; Janáky T; Kovács A; Gáspár R; Sztojkov-Ivanov A; Ducza E; Márki Á; Szabó-Révész P; Ambrus R
    Int J Pharm; 2020 Apr; 579():119166. PubMed ID: 32084574
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs.
    Kassem MA; Abdel Rahman AA; Ghorab MM; Ahmed MB; Khalil RM
    Int J Pharm; 2007 Aug; 340(1-2):126-33. PubMed ID: 17600645
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development and evaluation of intramuscularly administered nano/microcrystal suspension.
    Ma Z; Zhang H; Wang Y; Tang X
    Expert Opin Drug Deliv; 2019 Apr; 16(4):347-361. PubMed ID: 30827123
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cyclosporine A Nanosuspensions for Ophthalmic Delivery: A Comparative Study between Cationic Nanoparticles and Drug-Core Mucus Penetrating Nanoparticles.
    Yan R; Xu L; Wang Q; Wu Z; Zhang H; Gan L
    Mol Pharm; 2021 Dec; 18(12):4290-4298. PubMed ID: 34731571
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fabrication of surfactant-stabilized nanosuspension of naringenin to surpass its poor physiochemical properties and low oral bioavailability.
    Singh MK; Pooja D; Ravuri HG; Gunukula A; Kulhari H; Sistla R
    Phytomedicine; 2018 Feb; 40():48-54. PubMed ID: 29496174
    [TBL] [Abstract][Full Text] [Related]  

  • 34.
    Shariare MH; Altamimi MA; Marzan AL; Tabassum R; Jahan B; Reza HM; Rahman M; Ahsan GU; Kazi M
    Saudi Pharm J; 2019 Jan; 27(1):96-105. PubMed ID: 30662312
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Supercritical fluid (SCF)-assisted fabrication of carrier-free drugs: An eco-friendly welcome to active pharmaceutical ingredients (APIs).
    Kankala RK; Xu PY; Chen BQ; Wang SB; Chen AZ
    Adv Drug Deliv Rev; 2021 Sep; 176():113846. PubMed ID: 34197896
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Miconazole nanosuspensions: Influence of formulation variables on particle size reduction and physical stability.
    Cerdeira AM; Mazzotti M; Gander B
    Int J Pharm; 2010 Aug; 396(1-2):210-8. PubMed ID: 20600732
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Food proteins as novel nanosuspension stabilizers for poorly water-soluble drugs.
    He W; Lu Y; Qi J; Chen L; Hu F; Wu W
    Int J Pharm; 2013 Jan; 441(1-2):269-78. PubMed ID: 23194889
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of etoposide-loaded bovine serum albumin nanosuspensions for parenteral delivery.
    Wang Z; Li Z; Zhang D; Miao L; Huang G
    Drug Deliv; 2015 Jan; 22(1):79-85. PubMed ID: 24401038
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro and in vivo Evaluation of Ibuprofen Nanosuspensions for Enhanced Oral Bioavailability.
    Hedaya M; Bandarkar F; Nada A
    Med Princ Pract; 2021; 30(4):361-368. PubMed ID: 33823524
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The preparation and evaluation of water-soluble SKLB610 nanosuspensions with improved bioavailability.
    Huang Y; Luo X; You X; Xia Y; Song X; Yu L
    AAPS PharmSciTech; 2013 Sep; 14(3):1236-43. PubMed ID: 23934433
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.